Core Viewpoint - Zhongtai Securities maintains a "Buy" rating for HBM Pharmaceuticals (02142), projecting significant revenue and profit growth from the licensing agreement and milestone payments related to HBM7020 and HBM4003 [1] Group 1: Financial Projections - The company is expected to achieve total revenue of 1.4 billion, 1.594 billion, and 1.485 billion yuan for the years 2025 to 2027, an increase from previous estimates of 1.342 billion, 974 million, and 1.026 billion yuan [1] - Projected net profit attributable to the parent company is estimated at 665 million, 768 million, and 740 million yuan for the same period, up from previous estimates of 621 million, 307 million, and 432 million yuan [1] Group 2: Licensing Agreement - On February 23, 2026, HBM Pharmaceuticals announced a licensing and equity cooperation agreement with Solstice Oncology, granting exclusive development and commercialization rights for HBM4003 outside Greater China [1] - The agreement includes upfront payments totaling over 105 million USD, comprising a 50 million USD cash upfront payment, a 5 million USD near-term payment, and equity valued at over 50 million USD [1] - HBM Pharmaceuticals may also receive up to approximately 1.1 billion USD in milestone payments based on future specific events and tiered royalties based on net sales outside Greater China [1] Group 3: Product Characteristics - HBM4003 is the world's first fully human only heavy chain antibody entering clinical stages, targeting the CTLA-4 pathway, which has regained focus in immuno-oncology [2] - The product demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and high specificity in eliminating Treg cells expressing high levels of CTLA-4 in the tumor microenvironment [2] - Its unique mechanism of action shows potential for improved therapeutic efficacy while significantly reducing drug toxicity [2] Group 4: Clinical Trial Results - HBM4003 has shown good safety and strong efficacy in Phase I monotherapy trials, with potential indications including melanoma, non-small cell lung cancer, hepatocellular carcinoma, and neuroendocrine tumors [3] - Recent Phase II clinical data indicated positive efficacy in MSS colorectal cancer when combined with another treatment, achieving an overall response rate of 34.8% and a median progression-free survival of 4.2 months [3] - This performance is superior to existing CTLA-4 antibodies combined with PD-1 antibodies in treating advanced colorectal cancer, which typically shows progression-free survival of 2 to 3 months [3] Group 5: Cash Flow Impact - The upfront payment of over 105 million USD will directly enhance the company's cash flow [4] - This transaction, combined with the company's previous profit forecast for 2025 (estimated at 88 million to 95 million USD), will further solidify its robust cash flow [4] - The cumulative effects of multiple business development activities are expected to enhance the company's growth prospects in the medium term [4]